Diagnostic Value of Serum Syndecan-1 in Hepatocellular Carcinoma Associated with Hepatitis C virus in Egyptian Patients
Journal Title: Journal of Biomedical and Pharmaceutical Research - Year 2016, Vol 5, Issue 3
Abstract
Hepatocellular carcinoma (HCC) can benefit from tumor biomarkers’ diagnostic, therapeutic, and prognostic capabilities. There is a need for the use of accurate, rapid and inexpensive tumor marker with ultrasonography and computer tomography in appropriate diagnosis of HCC. The present study was designed to investigate the potential role of syndecan-1 as a diagnostic and prognostic, non-invasive biomarker for HCC. Also, to assess its accuracy, sensitivity and specificity in comparison with the usual recommended biomarker α-fetoprotein (AFP). This study is a cross sectional case–control study. The study included 45 patients with HCC associated with chronic HCV infection. In addition, 20 healthy subjects were included as a control group. AFP and syndecan-1were determined by enzyme immunoassay. Syndecan-1 serum level showed significantly marked elevation in HCC patients compared to control subjects (P<0.001). Analytical correlation study revealed highly significant positive correlation between syndecan-1 serum level with older patient over 55 years old , larger tumor size more than 2.5 cm and the presence of ascites ( P<0.001). Moreover, there was statistically significant increase in syndecan-1 levels in advanced Child-Pugh classifications (P<0.001). For determination the best diagnostic performance level of syndecan-1 represented by cut off value, receiver operative curve was drawn (ROC). Cut off point level were 4241 pg/ml with sensitivity 99.8% and 85% specificity. We conclude that syndecan-1 is an accurate biomarker in the diagnosis and prognosis of HCC, since its level is elevated in HCC patients and correlated with tumor size, patients over 55 years old, larger tumor size more than 2.5 cm, the presence of ascites and different stages of HCC. Further studies on large groups of patients are required to validate these results.
Authors and Affiliations
Firas A. Haj Ali| Biochemistry Department, Faculty of Pharmacy Mansoura University, Mansoura 35516, Egypt, Nahla H. Anber| Fellow of Biochemistry Emergency Hospital, Mansoura University, Mansoura 35516, Egypt, Amal M. El- Gayar| Biochemistry Department, Faculty of Pharmacy Mansoura University, Mansoura 35516, Egypt, Mamdouh M. El-Shishtawy| Biochemistry Department, Faculty of Pharmacy Mansoura University, Mansoura 35516, Egypt
ISOLATION AND EVALUATION OF DISINTEGRATING PROPERTIES OF BASELLA ALBA Linn. LEAF MUCILAGE IN TABLET FORMULATIONS
There are number of synthetic polymers are available in market for pharmaceutical formulations, but these synthetic polymers have certain disadvantages such as high cost, toxicity, environmental pollution during synthesi...
Management of Migraine: An Overview
Migraine headache is an episodic headache disorder. Most people who suffer from migraines get headaches that can be quite severe. The pain usually begins in the morning, on one side of the head. The word migraine is deri...
PREPARATION AND CHARACTERIZATION OF FAST DISNTEGRATING TABLETS OF HYDRALAZINE HYDROCHLORIDE USING DESIGN OF EXPERIMENT TECHNIQUE
Since the dose accuracy and patient’s compliance are important prerequisites for a long term treatment, there is a demand to develop a dosage form which can overcome difficulty in swallowing, inconvenience in administra...
ANTIDIABETIC ACTIVITY OF 2-AMINO-(5-FLUORO-2-OXOINDOLIN-3-YLIDENE) BENZOXAZOLE-5-CARBOHYDRAZIDE IN RATS
The present study was designed to evaluate the antidiabetic activity of new indole derivatives i.e 2-Amino-(5-fluoro-2-oxoindolin-3-ylidene) benzoxazole-5-carbohydrazide against alloxan induced diabetic rats. Alloxan (12...
SURGICAL RELEASE FOR TENNIS ELBOW-A CASE SERIES AT VIMS, BELLARY
OBJECTIVE: To assess the outcome of open release in the management of resistant tennis elbows, based on patient satisfaction. METHODS: This was an observational retrospective case series of 25 consecutive patients that u...